SCHEMBL20203473

SCHEMBL20203473

CC(C)c1ccc(N2CCNCCC2=O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.40
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
CHRNB2 P17787 3/20 0.36
CHRNA4 P43681 3/20 0.36
CACNA2D1 P54289 2/20 0.36
SLC6A2 P23975 1/20 0.36
F10 P00742 1/20 0.36
AKR1C3 P42330 1/20 0.36
CDK4 P11802 4/20 0.34
CDK6 Q00534 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
ESR1 P03372 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
CCND1 P24385 2/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15341607 0.88 SLC6A2 (0.41) HTR6PIM1CHRNB2CHRNA4SLC6A2
SCHEMBL21414348 0.87 HTR6 (0.37) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL20203458 0.84 HTR6 (0.35) HTR6CHRNB2CHRNA4CACNA2D1SLC6A2
SCHEMBL21509722 0.83 AKR1C3 (0.49) AKR1C3HRH3
SCHEMBL14525387 0.82 AKR1C3 (0.48) AKR1C3HRH3
SCHEMBL18291654 0.82 PIM1 (0.43) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL5158426 0.80 HTR6 (0.43) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL20203434 0.80 SLC6A2 (0.51) HTR6CHRNB2CHRNA4SLC6A2AKR1C3
SCHEMBL20203460 0.80 HPGD (0.39) CACNA2D1SLC6A2AKR1C3CDK4CDK6
SCHEMBL20037996 0.79 HTR6 (0.42) HTR6PIM1PIM3PIM2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
EP-3546458-B1 ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER TEIJIN PHARMA LTD (JP) 2021-01-06 EP disclosed
EP-3546458-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2019-10-02 EP disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 HTR6 615/4885PIM1 564/4885PIM3 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.